Selected research
Industry Research
Human Hepatitis B Immunoglobulin (HBIG) Industry Research Report 2026
Market perspective
The global Human Hepatitis B Immunoglobulin (HBIG) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Hepatitis B Immunoglobulin (HBIG) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Hepatitis B Immunoglobulin (HBIG) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Hepatitis B Immunoglobulin (HBIG) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Hepatitis B Immunoglobulin (HBIG) include Boya Bio-pharmaceutical, CSL, Grifols, Octapharma, Baxter, Bayer, Tiantan Biologic, Shuanglin Bio-pharmacy and Hualan Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Hepatitis B Immunoglobulin (HBIG) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Hepatitis B Immunoglobulin (HBIG) Market by Company
Boya Bio-pharmaceutical
CSL
Grifols
Octapharma
Baxter
Bayer
Tiantan Biologic
Shuanglin Bio-pharmacy
Hualan Biological
Shanghai RAAS
Sichuan Yuanda Shuyang
China Biologic
Shanghai Institute of Biological
Human Hepatitis B Immunoglobulin (HBIG) Segment by Type
100IU/Bottle Human Hepatitis B Immunoglobulin
200IU/Bottle Human Hepatitis B Immunoglobulin
400IU/Bottle Human Hepatitis B Immunoglobulin
Human Hepatitis B Immunoglobulin (HBIG) Segment by Application
Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
Unexpected Crowd of Hepatitis B Infection
Human Hepatitis B Immunoglobulin (HBIG) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Hepatitis B Immunoglobulin (HBIG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Hepatitis B Immunoglobulin (HBIG) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Hepatitis B Immunoglobulin (HBIG).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Hepatitis B Immunoglobulin (HBIG) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Hepatitis B Immunoglobulin (HBIG) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Hepatitis B Immunoglobulin (HBIG) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100IU/Bottle Human Hepatitis B Immunoglobulin
- 200IU/Bottle Human Hepatitis B Immunoglobulin
- 400IU/Bottle Human Hepatitis B Immunoglobulin
Applications
- Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
- Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
- Unexpected Crowd of Hepatitis B Infection
Companies covered
- Boya Bio-pharmaceutical
- CSL
- Grifols
- Octapharma
- Baxter
- Bayer
- Tiantan Biologic
- Shuanglin Bio-pharmacy
- Hualan Biological
- Shanghai RAAS
- Sichuan Yuanda Shuyang
- China Biologic
- Shanghai Institute of Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Market Size (2021-2032)
- 2.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales (2021-2032)
- 2.2.3 Global Human Hepatitis B Immunoglobulin (HBIG) Market Average Price (2021-2032)
- 2.3 Human Hepatitis B Immunoglobulin (HBIG) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100IU/Bottle Human Hepatitis B Immunoglobulin
- 2.3.3 200IU/Bottle Human Hepatitis B Immunoglobulin
- 2.3.4 400IU/Bottle Human Hepatitis B Immunoglobulin
- 2.4 Human Hepatitis B Immunoglobulin (HBIG) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
- 2.4.3 Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
- 2.4.4 Unexpected Crowd of Hepatitis B Infection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Hepatitis B Immunoglobulin (HBIG) Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Hepatitis B Immunoglobulin (HBIG) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Hepatitis B Immunoglobulin (HBIG), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Hepatitis B Immunoglobulin (HBIG), Product Type & Application
- 3.8 Global Manufacturers of Human Hepatitis B Immunoglobulin (HBIG), Established Date
- 3.9 Global Human Hepatitis B Immunoglobulin (HBIG) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boya Bio-pharmaceutical
- 4.1.1 Boya Bio-pharmaceutical Company Information
- 4.1.2 Boya Bio-pharmaceutical Business Overview
- 4.1.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.1.5 Boya Bio-pharmaceutical Recent Developments
- 4.2 CSL
- 4.2.1 CSL Company Information
- 4.2.2 CSL Business Overview
- 4.2.3 CSL Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSL Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.2.5 CSL Recent Developments
- 4.3 Grifols
- 4.3.1 Grifols Company Information
- 4.3.2 Grifols Business Overview
- 4.3.3 Grifols Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Grifols Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.3.5 Grifols Recent Developments
- 4.4 Octapharma
- 4.4.1 Octapharma Company Information
- 4.4.2 Octapharma Business Overview
- 4.4.3 Octapharma Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Octapharma Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.4.5 Octapharma Recent Developments
- 4.5 Baxter
- 4.5.1 Baxter Company Information
- 4.5.2 Baxter Business Overview
- 4.5.3 Baxter Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Baxter Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.5.5 Baxter Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Tiantan Biologic
- 4.7.1 Tiantan Biologic Company Information
- 4.7.2 Tiantan Biologic Business Overview
- 4.7.3 Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Tiantan Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.7.5 Tiantan Biologic Recent Developments
- 4.8 Shuanglin Bio-pharmacy
- 4.8.1 Shuanglin Bio-pharmacy Company Information
- 4.8.2 Shuanglin Bio-pharmacy Business Overview
- 4.8.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.8.5 Shuanglin Bio-pharmacy Recent Developments
- 4.9 Hualan Biological
- 4.9.1 Hualan Biological Company Information
- 4.9.2 Hualan Biological Business Overview
- 4.9.3 Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hualan Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.9.5 Hualan Biological Recent Developments
- 4.10 Shanghai RAAS
- 4.10.1 Shanghai RAAS Company Information
- 4.10.2 Shanghai RAAS Business Overview
- 4.10.3 Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Shanghai RAAS Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.10.5 Shanghai RAAS Recent Developments
- 4.11 Sichuan Yuanda Shuyang
- 4.11.1 Sichuan Yuanda Shuyang Company Information
- 4.11.2 Sichuan Yuanda Shuyang Business Overview
- 4.11.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.11.5 Sichuan Yuanda Shuyang Recent Developments
- 4.12 China Biologic
- 4.12.1 China Biologic Company Information
- 4.12.2 China Biologic Business Overview
- 4.12.3 China Biologic Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 China Biologic Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.12.5 China Biologic Recent Developments
- 4.13 Shanghai Institute of Biological
- 4.13.1 Shanghai Institute of Biological Company Information
- 4.13.2 Shanghai Institute of Biological Business Overview
- 4.13.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin (HBIG) Product Portfolio
- 4.13.5 Shanghai Institute of Biological Recent Developments
5 Global Human Hepatitis B Immunoglobulin (HBIG) Market Scenario by Region
- 5.1 Global Human Hepatitis B Immunoglobulin (HBIG) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021-2032
- 5.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2021-2026
- 5.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Region: 2027-2032
- 5.3 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Region: 2021-2032
- 5.3.1 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Region: 2021-2026
- 5.3.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Region: 2027-2032
- 5.4 North America Human Hepatitis B Immunoglobulin (HBIG) Market Facts & Figures by Country
- 5.4.1 North America Human Hepatitis B Immunoglobulin (HBIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
- 5.4.3 North America Human Hepatitis B Immunoglobulin (HBIG) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Hepatitis B Immunoglobulin (HBIG) Market Facts & Figures by Country
- 5.5.1 Europe Human Hepatitis B Immunoglobulin (HBIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
- 5.5.3 Europe Human Hepatitis B Immunoglobulin (HBIG) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Hepatitis B Immunoglobulin (HBIG) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Hepatitis B Immunoglobulin (HBIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Hepatitis B Immunoglobulin (HBIG) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Hepatitis B Immunoglobulin (HBIG) Market Facts & Figures by Country
- 5.7.1 South America Human Hepatitis B Immunoglobulin (HBIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
- 5.7.3 South America Human Hepatitis B Immunoglobulin (HBIG) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Hepatitis B Immunoglobulin (HBIG) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Hepatitis B Immunoglobulin (HBIG) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Hepatitis B Immunoglobulin (HBIG) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Hepatitis B Immunoglobulin (HBIG) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Type (2021-2032)
- 6.1.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Type (2021-2032)
- 6.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Type (2021-2032)
- 6.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Hepatitis B Immunoglobulin (HBIG) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Application (2021-2032)
- 7.1.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Human Hepatitis B Immunoglobulin (HBIG) Sales Market Share by Application (2021-2032)
- 7.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue by Application (2021-2032)
- 7.2.1 Global Human Hepatitis B Immunoglobulin (HBIG) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Hepatitis B Immunoglobulin (HBIG) Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Hepatitis B Immunoglobulin (HBIG) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Hepatitis B Immunoglobulin (HBIG) Value Chain Analysis
- 8.1.1 Human Hepatitis B Immunoglobulin (HBIG) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Hepatitis B Immunoglobulin (HBIG) Production Mode & Process
- 8.2 Human Hepatitis B Immunoglobulin (HBIG) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Hepatitis B Immunoglobulin (HBIG) Distributors
- 8.2.3 Human Hepatitis B Immunoglobulin (HBIG) Customers
9 Global Human Hepatitis B Immunoglobulin (HBIG) Analyzing Market Dynamics
- 9.1 Human Hepatitis B Immunoglobulin (HBIG) Industry Trends
- 9.2 Human Hepatitis B Immunoglobulin (HBIG) Industry Drivers
- 9.3 Human Hepatitis B Immunoglobulin (HBIG) Industry Opportunities and Challenges
- 9.4 Human Hepatitis B Immunoglobulin (HBIG) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst